Please use this identifier to cite or link to this item: http://adhlui.com.ui.edu.ng/jspui/handle/123456789/3794
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOBASEKI, A . O-
dc.contributor.authorCOKER, H. B.-
dc.date.accessioned2025-04-22T10:56:41Z-
dc.date.available2025-04-22T10:56:41Z-
dc.date.issued1988-
dc.identifier.citationAfr J Med Med Sci 1988, 17(1):27-31en_US
dc.identifier.issn1116-4077-
dc.identifier.urihttp://adhlui.com.ui.edu.ng/jspui/handle/123456789/3794-
dc.descriptionArticleen_US
dc.description.abstractNifedipine, being a nitro aromatic compound, is capable of undergoing reduction via hydroxylamino intermediate to an amine. Such an intermediate is a mutagenic culprit. The urinary metabolites of nifedipine were investigated in order to allay the fear of the existence of this metabolic route in humans. Nifedipine (20 mg) was administered twice daily for 2 weeks. No nitro-reduction product was detected over a 1- month period. Nifedipine lacks mutagenicity in the absence or presence of drug metabolizing microsomes in Salmonella typhimurium TA 98 and Salmonella typhimurium TA (100).en_US
dc.description.sponsorshipCOLLEGE OF MEDICINE, UNIVERSITY OF IBADAN, NIGERIAen_US
dc.language.isoenen_US
dc.publisherCOLLEGE OF MEDICINE, UNIVERSITY OF IBADAN, NIGERIAen_US
dc.subjectNifedipineen_US
dc.subjectmetabolic implicationen_US
dc.titleLack of mutagenicity of nifedipine: a possible metabolic implicationen_US
dc.typeArticleen_US
Appears in Collections:African Journal of Medicine and Medical Sciences

Files in This Item:
File Description SizeFormat 
Obaseki_Coker_Lack_1988.pdfArticle6.35 MBAdobe PDFView/Open


Items in COMUI (ADHL) are protected by copyright, with all rights reserved, unless otherwise indicated.